Honors Theses

Publication Date

4-20-2020

Abstract

Selinexor is currently being used in several clinical trials for cancer and has shown anti-cancer effects in combination with other chemotherapies. Clinical trials evaluating the use of selinexor in the treatment of triple negative breast cancer are limited, but in vitro studies show promising results in its ability to kill triple negative breast cancer cells. The mechanism by which this occurs, however, is not understood. The goal of this research was to determine the mechanism by which selinexor kills BT- 549 triple negative breast cancer cells.

Faculty Advisor

Dr. Marilyn Odom

Document Type

Honors Thesis

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.